Reversible Posterior Leukoencephalopathy Syndrome by Željka Petelin Gadže et al.
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1. Introduction 
Hinchey et al used the term „reversible posterior leukoencephalopathy syndrome“ in 1996 
to describe a syndrome characterized by headache, confusion, seizures and vision 
disturbances, including cortical blindness, connected with reversible changes on brain 
magnetic resonance imaging (MRI) which pointed to the white matter eodema, 
predominantly in the posterior brain regions (1).  Initially, this syndrome was believed to be 
secondary to arterial hypertension, with or without hypertensive encephalopathy, renal 
disease, or immunosuppressive therapy, such as cyclosporin A, tacrolimus and interferon-α. 
However, it has recently been identified in a wide variety of conditions, including 
eclampsia, hemolytic-uremic syndrome, connective tissue diseases, vasculitis, malignancies, 
chemotherapy, transfusions, intravenous  immunoglobulin (IVIG) therapy, therapy with 
erythropoietin, thrombotic thrombocytopenic purpura, porphyria, etc. (2-14).  
The normal response of the cerebral arterioles to acute rising blood pressure is sympathetic 
nerve-mediated vascular constriction to prevent increasing blood flow (autoregulation). But 
in the case of reversible posterior leukoencephalopathy syndrome, the response does not 
work well when there is excess high pressure or recent onset of a modest increase in blood 
pressure, and excess dilatation of the arterioles following disruption of cerebral small vessel 
endothelial cells (i.e., the blood-brain barrier) can occur, resulting in vasogenic brain edema. 
Therefore, disruption of cerebral vascular endothelial cells plays a critical role in the 
pathogenesis of reversible posterior leukoencephalopathy syndrome 
In this article we describe a case of a patient with clinical signs and neuroradiological 
presentation typicial for reversible posterior leukoencephalopathy syndrome.  
2. Case report 
A 72-year-old woman with a history of arterial hypertension in June 2009 suddenly 
developed headache, confusion, left homonymous hemianopsia, and left hemiparesis, 
associated with high blood pressure (220/110 mm Hg). From her case history we have 
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revealed that she was treated for pulmonary tuberculosis in the youth. Brain MRI performed 
in another institution revealed extensive white matter lesion in the right parietal and 
occipital lobe, splenium corpus callosum and left occipital lobe, suggestive of expansive 
process (Figure 1a and 1b). There were also bilateral chronic vascular lesions in the 
 
 
Fig. 1. Brain MRI in 72-year-old woman performed in June 2009 reveals extensive white matter 
lesion in the right parietal and occipital lobe, splenium corpus callosum and left occipital lobe. 
Figure 1a –  transversal MRI section, hyperintense lesion on T2 – weighted image. 
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Fig. 1b. Sagittal MRI section, hyperintense lesion on T2 – weighted image.  
subcortical white matter. Electroencephalogram (EEG) was diffuse paroxysmal 
dysrhythmic with focus of slow waves (frequency 2-3 Hz) above the parieto-occipital 
regions. Laboratory tests revealed hypercholesterolaemia and sideropenic anemia, as well 
as increased erythrocyte sedimentation rate (ESR) and fibrinogen levels, while complete 
blood cells count, electrolites, tests of liver and renal function, as well as other 
biochemical tests were within normal levels. After one month patient was transferred to 
our institution in order to perform stereotactic biopsy and pathohistological verification. 
In the meantime antihypertensive and antiedematous therapy was introduced with 
gradual normalization of blood pressure levels (130/80 mm Hg) and significant 
improvement of neurological status, with only discrete residual left hemiparesis. Control 
brain MRI revealed unexpected regression of the formerly described white matter lesion. 
MR spectroscopy verified increased levels of choline in the described area, with the 
inversion of the choline/creatine ratio, but with preserved values of N-acetylaspartate 
(NAA), and preserved NAA/choline ratio. In cerebrospinal fluid there were 5 
lymphocytes/mm3, 0.29 g/L of total proteins, oligoclonal bands were negative. 
Immunological blood tests were normal, as well as analysis of serum and cerebrospinal 
fluid on Borrelia burgdorferi, neurotropic viruses including HIV, syphilis, tuberculosis, 
mycosis, and serum on hepatitis.  
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Carcinoembryonic antigen (CEA), Ca 19.9, Ca 15.3, Ca 125, neuron specific enolase (NSE), 
CYFRA 21-1 were also negative, as well as findings of paraneoplastic antibodies (anti-Hu, 
anti-Yo and anti-Ri). Finding of visual evoked potentials pointed to neuronal lesion of the 
both optic pathways. Control EEG was diffuse paroxysmal dysrhythmic. Considering all 
mentioned findings, especially finding of the brain MRI and MR spectroscopy, which points 
to the leukoencephalopathy of vascular genesis (arterial hypertension), and improvement in 
neurological status, initially diagnosis of brain tumour was rejected and we did not proceed 
with the planned stereotactic brain biopsy.  
Control brain MRI performed after three months pointed to further regression of the 
described white matter lesion. At the moment patient is clinically stable and has normal 
neurological status. Brain MRI performed in October 2010 pointed to complete regression of 
the white matter lesion.  
3. Discussion  
Diagnostic criteria of the reversible posterior leukoencephalopathy syndrome include 
clinical and neuroradiological findings. Very often clinical manifestations are altered 
consciousness, headache, seizures and vision disturbances (1). According to the literature 
data, all patients do not develop all mentioned clinical symptoms. Our patient developed all 
mentioned clinical symptoms except seizures, however, she also had motorical weakness – 
left hemiparesis. 
Neuroradiological findings include reversible abnormalities of the white matter of the brain 
which present as hypodense areas on the brain CT, or hypointense areas on the T1-weighted 
images, hyperintense areas on the T2-weighted and FLAIR (“fluid-attenuated inversion 
recovery“) brain MR images, and isointense areas on the DWI (“diffusion-weighted 
imaging“)  sequences, which all points to vasogenic edema (15, 16).  Neuroradiological 
findings of the patient described in this paper correspond with the findings in the literature 
– edema was localized predominantly in the parieto-occipital brain regions. Although in 
most of the cases distribution of edema is symmetrical, there are cases with asymmetrical 
lesion localisation, as it was in the case of our patient.   
Involvement of grey matter and other brain regions including brainstem, cerebellum, basal 
ganglia and frontal lobes has also been described in the literature (17).  
The pathophysiology of RPLS appears to be multifactorial. The mechanism of the syndrome 
is a brain-capillary leak syndrome related to hypertension, fluid retention, and possibly the 
cytotoxic effects of immunosuppressive agents on the vascular endothelium. Severe 
hypertension per se is perhaps the most common cause. The sudden elevation in blood 
pressure exceeds the auto-regulatory capacity of the brain vasculature. A region of 
vasodilatation and vasoconstriction develops, especially in the arterial boundary zone, and 
there is breakdown of the blood-brain barrier with transudation of fluid and petechial 
hemorrhage. In experimental rats that were made suddenly hypertensive, these signs 
appeared and disappeared suddenly, within hours after relieving hypertension, suggesting 
the functional vascular changes and vasogenic edema. There is rapid resolution of clinical 
signs and symptoms and imaging abnormalities of reversible posterior 
leukoencephalopathy when blood pressure is lowered in such patients. While the 
reversibility of such vasogenic edema is most characteristic, it should be noted that it might 
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result in permanent neurological deficit and cerebral infarct. Uremic encephalopathies 
represent additional etiologies of RPLS that have a greater tendency for central distribution 
for unknown reason.  
The predilection for the more posterior involvement in leukoencephalopathy may be due to 
relatively fewer sympathetic innervations in the posterior cerebral vasculature, which helps 
auto-regulate the cerebral vessels during an acute rise in blood pressure. The calcarine and 
paramedian occipital lobe structures are usually spared. This distinguishes RPLS from 
bilateral infarction of the posterior cerebral artery territory. Simultaneous bilateral infarction 
of the posterior cerebral artery territory occurs in patients with embolism to the rostral 
basilar artery, but with “top of the basilar embolism” the calcarine regions are invariably 
involved and often there are accompanying thalamic and midbrain infarcts. It has been 
observed that an incorrect diagnosis of gliomatosis cerebri, progressive multifocal 
leukoencephalopathy, demyelinating disease, or infarction may be advanced on the basis of 
MRI, if all aspects of the clinical presentation are not mentioned to the radiologist. This may 
result in unnecessary invasive therapy and biopsies. In most cases the leukoencephalopathy 
is reversible within 1–2 weeks. However, prolonged seizure, hypertension, or both may 
result in permanent neurological deficit and cerebral infarction. The multiple cerebral 
infarctions may result in early dementia. A few patients may not recover completely or may 
have neurodevelopmental sequelae (18, 19).  
The role of the immunosuppressive therapy in the etiology of this syndrome is not so clear. 
According to the literature data, immunosuppressive or cytotoxic agents can cause this 
syndrome by toxic effect on the vascular endothelial cells or directly causing axonal damage 
(6,7,19,20).  
After extensive diagnostic evaluation that excluded brain tumour that was initially 
suspected, as well as other factors that could cause leukoencephalopathy such as systemic 
tissue diseases, renal diseases, inflammatory diseases and malignant diseases, we believe 
that the main cause of development of reversible posterior leukoencephalopathy syndrome 
in our patient was arterial hypertension, respectively abrupt and severe increase of arterial 
blood pressure. That supports improvement of clinical symptoms after correction of blood 
pressure, as well as finding of MR spectroscopy.   
4. Conclusion 
Early recognizing of the reversible posterior leukoencephalopathy syndrome is of great 
importance, because prompt regulation of elevated blood pressure, or in certain cases 
decreasing of dose or discontinuing immunosuppressive therapy , that is treatment of 
specific causes, can improve clinical condition of the patient and cause complete 
regression of the lesion of the brain white matter.  Great importance has the fact that the 
proper diagnosis, and distinction from expansive process, can stop invasive diagnostic 
procedures. If in some cases we suspect that patient could have reversible posterior 
leukoencephalopathy, it is better to wait few weeks and then repeat brain MRI before the 
patient undergoes to the invasive diagnostic procedure such as stereotactic brain biopsy.  
5. References 
[1] Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy 
syndrome. N Engl J Med 1996; 334: 494−500. 
www.intechopen.com
  
Management of CNS Tumors 
 
410 
[2] Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin associated hypertensive 
posterior leukoencephalopathy. Neurology 1997;49:686–9. 
[3] Ito Y, Niwa H, Iida T et al. Post-transfusion reversible posterior leukoencephalopathy 
syndrome with cerebral vasoconstriction. Neurology 1997;49:1174–5. 
[4] Laguna P, Martin T, Marchena MJ, Moya M. Posterior leukoencephalopathy reversible 
syndrome secondary to panarteritis nodosa. Med Clin (Barc) 1997;109:397–8. 
[5] Mathy I, Gille M, van Raemdonck F et al. Neurological complications of intravenous 
immunoglobulin (IVIG) therapy: An illustrative case of acute encephalopathy 
following IVIG therapy and a review of the literature. Acta Neurol Belg 1998;98:347- 
51. 
[6] Edwards MJ, Walker R, Vinnicombe S et al. Reversible posterior leukoencephalopathy 
syndrome following CHOP chemotherapy for diffuse large B- cell lymphoma. Ann 
Oncol  2001;12:1327–9. 
[7] Gimenez-Mesa E, Martinez-Salio A, Porta-Etessam J et al. Reversible posterior 
leukoencephalopathy in a patient with non-Hodgkin’s lymphoma after treatment 
with CHOP. An Med Interna 2001;18:591–3.  
[8] Utz N, Kinkel B, Hedde JP, Bewermeyer H. MR imaging of acute intermittent porphyria 
mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 
2001;43:1059-62. 
[9] Ozyurek H, Oguz G, Ozen S et al. Reversible posterior leukoencephalopathy syndrome: 
report of three cases. J Child Neurol 2005;20:990-3. 
[10] Cassano G, Góngora V, Zunino A, Roverano S, Paira S. Reversible posterior 
leukoencephalopathy in systemic lupus erythematosus with thrombotic 
thrombocytopenic purpura. J Clin Rheumatol 2007;13:55-7.  
[11] Bas DF, Oguz KK, Topcuoglu MA. Atypical reversible posterior leukoencephalopathy 
syndrome in thrombotic thrombocytopenic purpura. Intern Med 2008; 47:1931-4.  
[12] El Karoui K, Le Quintrec M, Dekeyser E, Et al. Posterior reversible encephalopathy 
syndrome in systemic lupus erythematosus. Nephrol Dial Transplant 2008; 23: 757-63. 
[13] Ergün T, Lakadamyalı H, Yılmaz A. Recurrent posterior reversible encephalopathy 
syndrome in a hypertensive patient with end-stage renal disease. Diagn Interv 
Radiol 2008; 14:182–5. 
[14] Ahn KJ, You WJ, Jeong SL, et al. Atypical manifestations of reversible posterior 
leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping. 
Neuroradiology 2004; 46:978–83. 
[15] Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible 
posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205-10.  
[16] Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without 
severe hypertension: Utility of diffusion weighted MRI. Neurology 1998;51:1369–76. 
[17] Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy: Findings on 
CT, MR imaging and SPECT imaging in 14 cases. AJR Am J Roentgenol 
1992;159:379–83. 
[18] Sundt T.  The cerebral autonomic nervous system: A proposed physiologic function 
and pathophysiologic response in subarachnoid hemorrhage and in focal cerebral 
ischemia. Mayo Clin  Proc 1973;48:127–37. 
[19] Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001; 77: 24-8. 
[20] Noda K, Fukae J, Fujishima K, Mori K, Urabe T, Hattori N, Okuma Y. Reversible 
cerebral vasoconstriction syndrome presenting as subarachnoid hemorrhage, 
reversible posterior leukoencephalopathy, and cerebral infarction. Intern Med. 
2011;50(11):1227-33.  
www.intechopen.com
Management of CNS Tumors
Edited by Dr. Miklos Garami
ISBN 978-953-307-646-1
Hard cover, 464 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Management of CNS Tumors is a selected review of Central Nervous System (CNS) tumors with particular
emphasis on pathological classification and complex treatment algorithms for each common tumor type.
Additional detailed information is provided on selected CNS tumor associated disorders.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Z ̌eljka Petelin Gadz ̌e, Davorka Milat, Sanja Hajns ̌ek, Branka Ribaric ́, Jasna Franjic ́ and Damir Petravić (2011).
Reversible Posterior Leukoencephalopathy Syndrome, Management of CNS Tumors, Dr. Miklos Garami (Ed.),
ISBN: 978-953-307-646-1, InTech, Available from: http://www.intechopen.com/books/management-of-cns-
tumors/reversible-posterior-leukoencephalopathy-syndrome
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
